ISG15 and prostate cancer: ISG15 has been reported to be aberrantly overexpressed in various malignant tumors, including high-grade serous ovarian cancer [28], cervical cancer [29], breast cancer [30], and prostate cancer [31], and is associated with poor prognosis [30].